X-ACKT_XPF-010-303: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Grants and Contracts Details

StatusActive
Effective start/end date8/9/238/9/25

Funding

  • Xenon Pharmaceuticals Incorporated: $14,931.00